Cervical Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Cervical Cancer
No standard treatment is available for patients with recurrent cervical cancer that has spread beyond the confines of a radiation or surgical field. For locally recurrent disease, pelvic exenteration can lead to a 5-year survival rate of 32% to 62% in selected patients.[1,2] These patients are appropriate candidates for clinical trials testing drug combinations or new anticancer agents.
The Gynecologic Oncology Group (GOG) has reported on several randomized phase III trials, (GOG-0179, GOG-0240 [NCT00803062]) in this setting with only one regimen being superior in overall survival (OS) to single-agent cisplatin administered intravenously at 50 mg/m² every 3 weeks.[3,4] However, incremental progress was made during the initial six randomized GOG trials that failed to reach their primary endpoint of improving survival. They showed that doubling the doses of cisplatin and adding either ifosfamide or paclitaxel to cisplatin increased the response rates and prolonged time to progression but at a cost of added toxicity and no prolongation of OS. The seventh randomized GOG trial in the setting of stage IVB and recurrent cervical cancer showed that adding topotecan at 0.75 mg/m² on the first 3 days of a 21-day cycle to cisplatin prolonged the median survival by 2.9 months (6.5–9.4 months; P = .017) with an unadjusted relative-risk estimate for survival of 0.76 (95% CI, .593–.979; = .017, one tailed) compared to cisplatin alone. Although the cisplatin/topotecan doublet is associated with more bone marrow suppression P compared to cisplatin alone, there was no associated decrement in quality of life found with the combination.
Nearly two decades ago, experts discovered a relationship between infection with HPV (human papillomavirus) and cervical cancer. Since then, these experts have learned much more about how HPV can lead to cervical cancer.
Here, what every woman and girl should know about this link.
Because it was superior to cisplatin alone in response rates and progression-free survival, patients with performance status of 0 or 1 tolerated the combination in the GOG-selected paclitaxel plus cisplatin (PC) regimen in the standard comparator arm for a subsequent trial with 513 patients comparing four cisplatin-based doublets (P-C vs. gemcitabine-C, vinorelbine-C vs. topotecan-C) in patients with advanced and recurrent cervical carcinoma. This study was closed early because of a futility analysis showing no likely differences to emerge. A full publication is awaited.